$2.70
-0.02 (-0.74%)
Open$2.76
Previous Close$2.72
Day High$2.76
Day Low$2.69
52W High$13.93
52W Low$1.90
Volume—
Avg Volume33.7K
Market Cap5.42M
P/E Ratio—
EPS$-1.63
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,253.0% upside
Current
$2.70
$2.70
Target
$36.53
$36.53
$23.38
$36.53 avg
$47.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.46M | 2.88M | 899.1K |
| Net Income | -3,116,902 | -2,332,040 | -268,437 |
| Profit Margin | -90.1% | -85.6% | -29.9% |
| EBITDA | -3,289,019 | -2,597,529 | -429,552 |
| Free Cash Flow | — | — | -251,567 |
| Rev Growth | +20.3% | +20.3% | -1.1% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |